Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.17
-0.02 (-7.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $762987.00 · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$21M
P/E
5.8x
↓EV/EBITDA
6.4x
↓ROE
1.7%
↑Gross Margin
21.1%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+343.2%
FCF CAGR
—
FCF margin
3.4%
FCF / Net income
5.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $73.4M · net income $484849.0 · FCF $2.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $73.4M | $73.4M | $57.2M | $35.3M | $842491.00 |
| Net Income | $484849.00 | $484849.00 | $615906.00 | $-913857.00 | $-4.7M |
| EBITDA | $2.9M | $2.9M | $2.9M | $1.7M | $-3.4M |
| EPS | — | — | 0.01 | -0.01 | -0.06 |
| Gross Margin | 21.1% | 21.1% | 19.5% | 21.5% | -50.8% |
| Operating Margin | 2.2% | 2.2% | 2.8% | -0.7% | -476.7% |
| Net Margin | 0.7% | 0.7% | 1.1% | -2.6% | -561.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.28 | 0.26 | 0.72 |
| Current Ratio | 4.20 | 4.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.5M | $2.5M | $762987.00 | $-4.4M | $-2.7M |
| Returns | |||||
| ROE | 1.7% | 1.7% | 2.2% | -3.7% | -30.7% |
| Valuation | |||||
| P/E | 5.83 | 5.83 | 30.00 | — | — |
| EV/EBITDA | 6.43 | 6.43 | 13.35 | 127.96 | — |
| P/B | 0.71 | 0.71 | 1.27 | 8.82 | 7.24 |
| Growth & Yield | |||||
| Revenue Growth | 28.2% | 28.2% | 61.9% | 4094.9% | — |
| EPS Growth | — | — | 200.0% | 83.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
-30.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.